The survival analysis, after HSCT stratification, showed that for WT1-mutated pediatric AML patients, HSCT conferred a favorable prognostic impact with a trend of better 5-year EFS (42.9 ± 18.7% vs 22.3 ± 7.0% for chemotherapy-only; P=0.316) and OS (57.1 ± 18.7% vs 43.6 ± 8.2% for chemotherapy-only; P=0.483) (Figures 3A, B). Here, WT1 is linked to acute myeloid leukemia.